Tharimmune (NASDAQ:THAR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Tharimmune (NASDAQ:THAR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
New Crypto Deals Put Retail at Risk After $17 Billion Wipeout [Yahoo! Finance]
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy